Lantern Pharma LTRN Q1 2026 Earnings EPS Beats Estimates by 183 Despite Absence of Revenue STAA Q1 2026 Earnings Strong EPS Surprise of 45385 Driven by Operational Efficiency MGA Q1 2026 Earnings Strong EPS Beat of 33 Drives Positive Market Reaction DaVita Q1 2026 Earnings EPS Surges Past Estimates by 226 Yet Stock Barely Moves Encompass Health Q1 2026 Earnings EPS Surpasses Estimates by 58 Amid Mixed Market Reaction ERAS Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Climbs